EGFR and non-small cell lung carcinoma: Multiple large-sample clinical studies have shown that in advanced NSCLC patients with EGFR mutation detected by histological specimens, the median PFS can reach 9.2 to 18.9 months when treated with EGFR-TKIs [20–22].